Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of synthetic DNA- and RNA- based drug candidates that are designed to modulate immune responses mediated through toll-like receptors (TLRs). Autoimmune and Inflammatory Disease Program The company has two drug candidates in clinical development for the treatment of autoimmune and inflammatory diseases. IMO-3100: IMO-3100 is an antagonist of TLR7 and TLR9. In 2012, the company has completed a randomized double-blinded, placebo-controlled Phase 2 clinical trial of IMO-3100 that it conducted in 44 adult patients with moderate to severe plaque psoriasis. IMO-8400: IMO-8400 is a TLR7, TLR8, and TLR9 antagonist. The company is conducting a Phase 1 clinical trial to evaluate the safety and pharmacodynamics of IMO-8400 in healthy subjects. It also plans to initiate a Phase 2 clinical trial of IMO-8400 in patients with lupus in 2013. Vaccine Adjuvants In 2012, the company announced that Merck Sharp & Dohme Corp. (Merck & Co.) had selected its TLR7, TLR8 or TLR 9 agonists for evaluation and use as vaccine adjuvant candidates in the fields of cancer, infectious diseases, and Alzheimer’s disease. Additional TLR Programs In addition to its TLR programs in autoimmune and inflammatory diseases, and its collaboration with Merck & Co. for the use of TLR7, TLR8, and TLR9 agonists as vaccine adjuvants, the company has identified TLR drug candidates for applications in the treatment of cancer, hematological malignancies and respiratory diseases, and created TLR3 agonists for use as vaccine adjuvants. Cancer: The company’s cancer program comprises IMO-2055, which has completed a Phase 1b clinical trial of IMO-2055 in combination with erlotinib and bevacizumab in patients with advanced non-small cell lung cancer; a Phase 1b clinical trial of IMO-2055 in combination with cetuximab and the chemotherapy regimen FOLFIRI in patients with advanced colorectal cancer; a randomized Phase 2 clinical trial of IMO-2055 in combination with cetuximab in patients with squamous cell carcinoma of the head and neck; and a Phase 2 clinical trial of IMO-2055 monotherapy in patients with renal cell carcinoma. Hematological Malignancies: The company has selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological malignancies. The company has conducted preclinical studies in mouse models combining IMO-4200 with ofatumumab, an anti-CD20 antibody, and, in separate experiments, with rituximab, an anti-CD20 antibody, plus a chemotherapy agent, fludarabine or bendamustine. In all of these combinations, IMO-4200 improved antitumor activity, increased survival, and enhanced the immunological mechanism of action of the antibody in preclinical models. Respiratory Diseases: The company is also developing IMO-2134, a compound which was evaluated in a Phase 1 clinical trial for the treatment of respiratory diseases, such as asthma and allergy. Vaccine Adjuvants: The company has created proprietary TLR3 agonists for potential use as vaccine adjuvants. In preclinical models, its TLR3 agonists stimulated immune responses, including promoting an increased production of antigen-specific antibodies and cytotoxic T cells as compared to responses induced by the antigen alone in preclinical vaccination studies. Gene Silencing Oligonucleotides (GSOs): The company has also created GSOs, which are designed to inhibit the production of disease-associated proteins by targeting RNA. Research and Development Expenses For the year ended December 31, 2012, the company spent approximately $13.7 million on research and development activities. Patents, Proprietary Rights, and Trade Secrets As of January 31, 2013, the company owned 66 U.S. patents and patent applications and 161 patents and patent applications throughout the rest of the world for its TLR-targeted immune modulation technologies. These patents and patent applications include novel chemical compositions of matter and methods of use for its immune modulatory compounds, including IMO-3100, IMO-8400, and IMO-2055. These patents expire at various dates ranging from 2017 to 2031. As of January 31, 2013, the company also owned three U.S. patent applications and six corresponding worldwide patent application for its GSO compounds and methods of their use. Patents issuing from these applications, if any, would expire at their earliest in 2030. In addition to its TLR-targeted patent portfolio, the company owns or holds licenses of patents and patent applications related to antisense technology. As of January 31, 2013, its antisense patent portfolio included 93 U.S. patents and patent applications and 85 patents and patent applications throughout the rest of the world. Some of the patents and patent applications in its antisense portfolio were in-licensed. These in-licensed patents expire at various dates ranging from 2013 to 2022. Significant Events In August 2013, Idera Pharmaceuticals, Inc. announced that it has entered into a Materials Cooperative Research and Development Agreement with the National Cancer Institute to evaluate the company's Toll-like receptor antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas. Competition The company’s principal competitor developing TLR-targeted compounds for autoimmune and inflammatory diseases is Dynavax Technologies Corporation with its collaborator, GlaxoSmithKline plc. History Idera Pharmaceuticals, Inc. was founded in 1989.
idera pharmaceuticals inc
167 Sidney Street
Cambridge, MA 02139
|No competitor information is available for IDRA.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- San Francisco, CA | SmartrecruitersPosted: Apr 09
- Washington, DC | DC BarPosted: Apr 09
- Washington, DC | DC BarPosted: Apr 09
- Carlinville, IL | KarmakPosted: Mar 25
Sponsored Financial Commentaries
To contact IDERA PHARMACEUTICALS INC, please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.